A potential novel marker for human prostate cancer:: voltage-gated sodium channel expression in vivo

被引:124
作者
Diss, JKJ
Stewart, D
Pani, F
Foster, CS
Walker, MM
Patel, A
Djamgoz, MBA
机构
[1] Univ London Imperial Coll Sci & Technol, Dept Biol Sci, Neurosci Solut Canc Res Grp, London SW7 2AZ, England
[2] UCL, Inst Child Hlth, Med Mol Biol Unit, London, England
[3] Univ Liverpool, Dept Cellular & Mol Pathol, Liverpool L69 3BX, Merseyside, England
[4] St Marys Hosp, Imperial Coll Sch Med, Dept Histopathol, London, England
[5] St Marys Hosp, Imperial Coll Sch Med, Dept Urol, London, England
关键词
Na(v)1.7; immunohistochemistry; real-time PCR; receiver-operating; characteristics curve; diagnosis;
D O I
10.1038/sj.pcan.4500796
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Functional expression of voltage-gated sodium channel alpha-subunits (VGSC alpha s), specifically Na(v)1.7, is associated with strong metastatic potential in prostate cancer (CaP) in vitro. Furthermore, VGSC activity in vitro directly potentiates processes integral to metastasis. To investigate VGSC alpha expression in CaP in vivo, immunohistochemistry and real-time PCR were performed on human prostate biopsies (n>20). VGSC alpha immunostaining was evident in prostatic tissues and markedly stronger in CaP vs non-CaP patients. Importantly, RT-PCRs identified Na(v)1.7 as the VGSC alpha most strikingly upregulated (similar to 20-fold) in CaP, and the resultant receiver-operating characteristics curve demonstrated high diagnostic efficacy for the disease. It is concluded that VGSC alpha expression increases significantly in CaP in vivo and that Na(v)1.7 is a potential functional diagnostic marker.
引用
收藏
页码:266 / 273
页数:8
相关论文
共 50 条
[1]   Expression and activity of potassium ion channels in human prostate cancer [J].
Abdul, M ;
Hoosein, N .
CANCER LETTERS, 2002, 186 (01) :99-105
[2]  
Abdul M, 2002, ANTICANCER RES, V22, P1727
[3]  
Abdul M, 2001, ANTICANCER RES, V21, P2045
[4]  
Anderson JD, 2003, MOL CANCER THER, V2, P1149
[5]   Growth factors and their receptors: New targets for prostate cancer therapy [J].
Barton, J ;
Blackledge, G ;
Wakeling, A .
UROLOGY, 2001, 58 (2A) :114-122
[6]   Voltage-gated Na+ channels confer invasive properties on human prostate cancer cells [J].
Bennett, ES ;
Smith, BA ;
Harper, JM .
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2004, 447 (06) :908-914
[7]  
Bostwick DG, 1996, PROSTATE, V29, P117
[8]   Prostate-specific antigen best practice policy - part I: Early detection and diagnosis of prostate cancer [J].
Carroll, P ;
Coley, C ;
McLeod, D ;
Schellhammer, P ;
Sweat, G ;
Wasson, J ;
Zietman, A ;
Thompson, I .
UROLOGY, 2001, 57 (02) :217-224
[9]   Prostate-specific antigen best practice policy - part II: Prostate cancer staging and post-treatment follow-up [J].
Carroll, P ;
Coley, C ;
McLeod, D ;
Schellhammer, P ;
Sweat, G ;
Wasson, J ;
Zietman, A ;
Thompson, I .
UROLOGY, 2001, 57 (02) :225-229
[10]   Molecular and genetic prognostic factors of prostate cancer [J].
Chakravarti, A ;
Zhai, GG .
WORLD JOURNAL OF UROLOGY, 2003, 21 (04) :265-274